Love-Pharma Goes Live On The Canadian Stock Exchange
The Cannabidiol (CBD)/Tetrahydrocannabinol (THC) market has been growing at an exponential rate, especially with the favorable laws in North America (Mostly United States and Canada). According to Fortune Business Insights, the CBD market is projected to grow to a whopping $55.8 billion by 2028. The United States alone is the biggest market for CBD as it accounts for more than 50% of the entire global CBD market. Another report by Businesswire showed that the Cannabidiol market is estimated to hit $2.73 billion by the end of 2021 and is expected to have a compound annual growth rate (CAGR) of 18.5% between 2021-2026.
The booming CBD market has attracted a lot of companies and businesses to the industry, especially in the pharmaceutical sector. One of the top companies at the forefront of the CBD market is Love Pharma Inc. In its quest to further reinforce its hold on the CBD market and allow product users and investors to access the Company’s shares, Love Pharma is live on the Canadian Stock Exchange (CSE).
According to Love Pharma’s CEO, Zachary Stadnyk, the company is eyeing the global market. They intend to utilize different channels like online shops, multi-level marketing (MLM), direct-to-consumer, and retail brick & mortar models. Getting listed on the Canadian Stock Exchange (CSE) further reveals the rising market demand for CBD/THC-based products. Aside from the Canadian Stock Exchange, Love Pharma has also been listed on the Frankfurt Stock Exchange (FSE) in Germany. Listing on the CSE is a huge milestone for the Company as both investors and non-investors can have access to the company’s shares.
Overview of the Love Pharma Company
Love Pharma Inc. is an alternative health pharmaceutical company with a major focus on psychedelics, nutraceuticals, and intimacy enhancement products. The company has disrupted the pharmaceutical industry with its highly sought-after psychedelic and cannabis-based products. Love Pharma holds an exclusive license to produce, market, and distribute patent-protected pharmaceutical products.
The CEO, Zachary Stadnyk said the company is strategically positioned to fill the growing demand in the global CBD and psychedelic market. As part of their strategy, Love Pharma Inc. bought the BC-based Kick Pharmaceuticals. This purchase gave the company exclusive rights and license to produce and market six pharmaceutical and therapeutic products in Europe and North America.
In order to meet the psychedelic demand, Love Pharma Inc. is currently working on a biosynthetic psilocybin-infused strip.
Love Pharma Products
The products of Love Pharma are designed to provide sexual and mental wellness by leveraging nutraceuticals and psychedelics. These products include:
The Auralief oral strips offer a user-friendly method of administering the mental and physiological benefits of THC and CBD. They are paper-thin and easily dissolve under the tongue to administer the CBD/THC. The product makes hemp use very accessible to virtually everyone. Auralief strips’ low profile nature offers a comfortable and convenient user experience while also ensuring sleep improvement and providing temporary relief from pain, inflammation, and stress.
Bloom gel increases vaginal blood circulation, creating vulvar and clitoral stimulation, lubrication, and increased sensation. The product is designed for both solo and partnered sexual activity in order to improve sexual arousal.
Love Pharma and its partners are currently working on meeting the high psychedelic demand. According to the team, psychedelic is an underestimated market. According to the Research and Markets report, the psychedelic market is valued at $4.7 billion and is expected to hit $7.58 billion by 2026 at a compound annual growth rate (CAGR) of 13.3%.
According to Love Pharma CEO, the company’s shareholders will continue to enjoy mergers and acquisitions that are in line with the company's intellectual property portfolio. Also, being officially listed on the Canadian Securities Exchange further boosts the confidence of investors and shareholders.